Oncology

The FDA has approved nivolumab plus ipilimumab injections for intravenous use to treat hepatocellular carcinoma in patients who have been previously treated with sorafenib.

Novel approaches such as telemedicine may be a way to reach rural patients with cancer, according to a panel discussion at the Hematology/Oncology Pharmacists Association 2020 Meeting

Lesbian, gay, bisexual, transgender, and queer (LGBTQ) patients with cancer face specific barriers when seeking medical care, but pharmacists and other medical professionals can take specific steps to reduce the gaps in care.

Individuals with the highest mercury levels in their blood were 79% more likely to report having had a non-melanoma skin cancer than those with the lowest levels.

Due to the uniqueness of each disease state and motivations of each player in the market to capture revenue from the growing industry, there is an abundance of specialty pharmacy solutions available in the market.

Pharmacy Times will be on-site next week to provide coverage of the sessions, recaps of the panel discussions, and interviews with the experts.

Gilead has agreed to pay $95.50 per share in cash for Forty Seven Inc, adding the 5-year old biotechnology company to bolster its portfolio of oncology drugs.

A study offers evidence that chimeric antigen receptor T-cell therapy may not only extend patients’ survival, but also improve their quality of life after treatment.

AL101 is a potent, selective, injectable small molecule gamma secretase inhibitor and was granted Orphan Drug designation in May 2019 for the treatment of ACC.

Pharmacists should be aware of what drug repurposing is and how it occurs as due to the vast amount of opportunities that exist.

Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.

A session on the use of biosimilars, a topic that many pharmacists identify to be of growing importance in their practices, concluded the 2019 Directions in Oncology Pharmacy conference.

PARP inhibitors are novel therapies with indication focused on ovarian cancer; however, new agents are being studied for other cancers as well.

With cases of melanoma increasing more rapidly than those of other malignancies (especially in men), no conference on oncology pharmacy would be complete without a session covering this topic and its expansion of treatment options.

Many people are unaware that acute myeloid leukemia (AML) is the leading cause of acute leukemia in adults.

Approximately 73,000 NEW cases of renal cell carcinoma (RCC) are expected to be diagnosed in 2019 in the United States, with up to 70% of these cases anticipated to be clear-cell subtype.

Depending on the amount consumed, intake of dairy milk can increase the risk of breast cancer by up to 80%, according to new research from Loma Linda University Health.

Oncologists have grown increasingly concerned that high costs create ‘financial toxicity’ and may keep patients from getting needed treatments.

Researchers report promising activity with a novel drug that targets a key molecular driver of clear cell renal cell carcinoma in patients with metastatic disease.

This is the first newly approved therapy for high risk locally advanced squamous cell carcinoma of LA-SCCHN in 25 years.

Prior authorization (PA) requirements, cost, and other factors can lead to turnaround times of up to 3 weeks, delaying the start of therapy and creating substantial anxiety for patients.

Two recently approved leukemia drugs could be enlisted against treatment-resistant lung cancer.

Officials from the FDA have approved a supplemental New Drug Application (sNDA) for neratinib (NERLYNX, Puma Biotechnology) in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.

The research resulted in nearly 50 new drugs with previously unrecognized anti-cancer activity.

Patients with CLL may have genetic mutations that predict response to different treatments.

Current FDA-approved CAR-T cell therapies express CARs recognizing CD19, which is expressed on the surface of almost all B cells, making these therapies specific for B-cell malignancies.

As the growth of specialty continues at a record pace, pharmacy must keep up with new distribution trends as an oncology product’s supply chain of a product can take many paths.

Monotherapy with talazoparib demonstrated encouraging antitumor activity in patients with DNA damage repair mutations and docetaxel pretreated metastatic castration-resistant prostate cancer.

HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.

To stay up-to-date on the latest in oncology pharmacy, make sure to check out the slate of programming that will be offered this year through our Directions in Oncology PharmacyTM series.